In a significant move to strengthen India’s animal healthcare ecosystem and reduce dependency on imports, the Technology Development Board (TDB), under the Department of Science & Technology (DST), has extended financial assistance to M/s Biovet Private Limited, Malur, Karnataka, for a project titled “Development and Commercialization of Veterinary Hormones.”
The project aims to establish a dedicated manufacturing facility for the commercial production of key veterinary reproductive hormones, including GnRH analogues—Gonadorelin and Buserelin acetate—and the prostaglandin analogue Cloprostenol . These hormones are critical for livestock reproduction management and therapeutic interventions for reproductive disorders, playing a vital role in improving breeding efficiency and sustainable animal production .
Currently, there is no commercial-scale production of these hormones indigenously developed in India, leading to a complete dependence on imports and higher costs for farmers . The proposed facility will enable domestic manufacturing of these hormone agonists, reducing import reliance, lowering costs, and ensuring wider accessibility for livestock farmers across the country. The initiative is also expected to generate substantial foreign exchange savings while creating new export opportunities in the global veterinary market .
The project will leverage Biovet’s established expertise in biotechnology-based veterinary products, including biologicals and vaccines, to expand into a specialized vertical of hormone and therapeutic product manufacturing. By integrating indigenous process development with commercial-scale production, the initiative aims to strengthen India’s capabilities in high-value veterinary pharmaceuticals .
Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, “Development of indigenous veterinary hormone manufacturing capacity is strategically important for strengthening animal husbandry and supporting farmers’ livelihoods. Through this project, TDB is facilitating import substitution, promoting domestic biotechnology capabilities, and enabling affordable access to critical reproductive therapeutics” .
The promoters of Biovet Private Limited added, “TDB’s support will enable us to establish world-class manufacturing infrastructure for veterinary hormones and serve both domestic and international markets. This initiative will enhance accessibility of essential reproductive therapeutics and contribute to the growth and sustainability of India’s livestock sector” .
The project aligns with TDB’s mandate to provide financial assistance for the commercialization of indigenous technologies and industrial R&D outcomes. By supporting domestic production of critical veterinary hormones, TDB continues to promote Aatmanirbharta in animal healthcare, strengthen the livestock value chain, and contribute to improved income and productivity for farmers across the country .